Financials

  • Market Capitalization 441.88 M
  • Employee 156
  • Founded 1988
  • CEO Gerard Michel
  • Website www.delcath.com
  • Headquarter Delaware, United States
  • FIGI BBG000BY2VF5
  • Industry Medical Devices
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
144.29
Price to sales ratio
4.73

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2970
PACB
Pacific Biosciences of California, Inc. - Common Stock
1.51 USD+1.34%-4.43%+12.69%+2.72%469.01 M USD
2990
VREX
Varex Imaging Corporation - Common Stock
10.23 USD-5.28%-4.12%-9.47%+27.88%430.68 M USD
3131
ELMD
Electromed, Inc. Common Stock
45.86 USD-0.13%-0.24%+20.21%+85.07%379.72 M USD
3199
CATX
Perspective Therapeutics, Inc. Common Stock
3.03 USD-2.26%-16.07%+0.33%-27.68%345.56 M USD

Frequently asked questions about Delcath Systems, Inc. - Common Stock

What is the Delcath Systems, Inc. - Common Stock stock price today?

The current price of Delcath Systems, Inc. - Common Stock (DCTH) is 12.8. Over the past 24 hours, the stock has changed by -0.54%. Follow the DCTH chart for real-time price dynamics.

What is the stock ticker of Delcath Systems, Inc. - Common Stock?

Delcath Systems, Inc. - Common Stock trades under the ticker DCTH. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Delcath Systems, Inc. - Common Stock stock going up?

DCTH has changed by -3.25% over the last week, +6.22% over the last month, and +23.79% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Delcath Systems, Inc. - Common Stock net income for the last quarter?

Delcath Systems, Inc. - Common Stock reported net income of -1.07 M for the last quarter. The previous quarter showed -1.9 M, which means net income changed by +43.57%.

How many employees does Delcath Systems, Inc. - Common Stock have?

As of the latest available data, Delcath Systems, Inc. - Common Stock has 156 employees. Workforce size can provide additional context about the company's scale and operations.

What is Delcath Systems, Inc. - Common Stock EBITDA?

Delcath Systems, Inc. - Common Stock EBITDA is -1.53 M, and its EBITDA margin is -6.14%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Delcath Systems, Inc. - Common Stock stock?

You can buy Delcath Systems, Inc. - Common Stock (DCTH) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Delcath Systems, Inc. - Common Stock stock?

Investing in Delcath Systems, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the DCTH chart and related analysis on metatrader.com as part of your research.

Delcath Systems, Inc. - Common Stock

Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.

News